Delcath Systems Reports 20% Revenue Growth in Q2 2026, Driven by HEPZATO KIT Demand

Delcath Systems, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $29.1 million, a 20% increase from $24.2 million in the same period of 2025. For the first half of 2026, revenue reached $54.1 million, up from $43.9 million year-over-year. The growth was primarily driven by the continued commercial expansion and demand for the HEPZATO KIT, which generated $27.2 million in the second quarter, compared to $22.5 million in the prior year. The company reported a net income of $2.7 million for the second quarter, slightly down from $2.7 million in the same quarter of 2025, while the net income for the first half of 2026 was $1.6 million, down from $3.8 million in the previous year.

Delcath's operating expenses increased to $23.8 million in the second quarter of 2026, compared to $18.2 million in the same quarter of 2025. This rise was attributed to higher research and development costs, which surged to $10.4 million from $6.9 million, reflecting the company's ongoing clinical trials and expansion of its clinical team. Selling, general, and administrative expenses also rose to $13.4 million from $11.4 million, driven by marketing and personnel costs associated with commercial activities.

The company’s balance sheet showed total assets of $137.0 million as of June 30, 2026, an increase from $123.6 million at the end of 2025. Cash and cash equivalents rose to $47.5 million, up from $43.5 million, while short-term investments increased to $48.4 million. Delcath's total liabilities also increased to $15.9 million from $12.4 million, primarily due to higher accounts payable and accrued expenses. The company’s stockholders’ equity grew to $121.1 million, up from $111.2 million, reflecting the issuance of common stock and retained earnings.

Strategically, Delcath continues to focus on its lead product, the HEPZATO KIT, which received FDA approval in August 2023 for treating uveal melanoma with hepatic metastases. The first commercial use of HEPZATO occurred in January 2024. The company is also advancing its clinical development programs, including ongoing Phase 2 trials for HEPZATO in combination with standard care for liver-dominant metastatic colorectal cancer and metastatic breast cancer. Delcath anticipates that these trials will support increased clinical adoption and reimbursement for its products.

Looking ahead, Delcath expects to maintain its current cash position to support operations for at least the next 12 months. The company is actively monitoring its liquidity and capital requirements, which will depend on various factors, including the progress of clinical trials and product commercialization efforts. Delcath remains committed to expanding its market presence and addressing unmet medical needs in the oncology space, particularly for liver-directed therapies.